A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?

International Journal of Cardiology

Volumn 228, Issue , 2017, Pages 198-200

  Rossello, Xavier ^a   Yellon, Derek M ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardioprotection; Diabetes; GLP 1 analogue; SGLT2 inhibitor

Indexed keywords

EMPAGLIFLOZIN; GLUCAGON LIKE PEPTIDE 1; LIRAGLUTIDE; PLACEBO; SODIUM GLUCOSE COTRANSPORTER 2; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG EFFECT; EDITORIAL; GLYCEMIC CONTROL; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK REDUCTION; WEIGHT REDUCTION; CARDIOVASCULAR DISEASE; COMPLICATION;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; LIRAGLUTIDE;

EID: 84995685476     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.11.246     Document Type: Editorial

References (14)

1. [1] Rossello, X., Yellon, D.M., A critical review on the translational journey of cardioprotective therapies!. Int. J. Cardiol. 220 (2016), 176–184, 10.1016/j.ijcard.2016.06.131.
2. [2] Chinda, K., Palee, S., Surinkaew, S., Phornphutkul, M., Chattipakorn, S., Chattipakorn, N., Cardioprotective effect of dipeptidyl peptidase-4 inhibitor during ischemia-reperfusion injury. Int. J. Cardiol. 167 (2016), 451–457, 10.1016/j.ijcard.2012.01.011.
3. [3] Savarese, G., D'Amore, C., Federici, M., De Martino, F., Dellegrottaglie, S., Marciano, C., et al. Effects of dipeptidyl peptidase 4 inhibitors and sodium-glucose linked cotransporter-2 inhibitors on cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis. Int. J. Cardiol. 220 (2016), 595–601, 10.1016/j.ijcard.2016.06.208.
4. [4] Bose, A.K., Mocanu, M.M., Carr, R.D., Brand, C.L., Yellon, D.M., Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 54 (2005), 146–151 ( http://www.ncbi.nlm.nih.gov/pubmed/15616022 (accessed June 6, 2016).
5. [5] Lønborg, J., Vejlstrup, N., Kelbæk, H., Bøtker, H.E., Kim, W.Y., Mathiasen, A.B., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J. 33 (2012), 1491–1499, 10.1093/eurheartj/ehr309.
6. [6] Ghosh, R.K., Bandyopadhyay, D., Hajra, A., Biswas, M., Gupta, A., Cardiovascular outcomes of sodium-glucose cotransporter 2 inhibitors: a comprehensive review of clinical and preclinical studies. Int. J. Cardiol. 212 (2016), 29–36, 10.1016/j.ijcard.2016.02.134.
7. [7] Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N. Engl. J. Med. 369 (2013), 1317–1326, 10.1056/NEJMoa1307684.
8. [8] White, W.B., Cannon, C.P., Heller, S.R., Nissen, S.E., Bergenstal, R.M., Bakris, G.L., et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N. Engl. J. Med. 369 (2013), 1327–1335, 10.1056/NEJMoa1305889.
9. [9] Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med., 373, 2015, 10.1056/NEJMoa1501352 (150608133014007).
10. [10] Pfeffer, M.A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H.C., Køber, L.V., et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373 (2015), 2247–2257, 10.1056/NEJMoa1509225.
11. [11] Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med., 373, 2015, 10.1056/NEJMoa1504720 (150917085022006).
12. [12] Steven, M.P., Gilbert, D.H., Kirstine, B.-F., Peter, K., Johannes, M.F., Michael, N.A., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322, 10.1056/NEJMoa1603827.
13. [13] Marso, S.P., Bain, S.C., Consoli, A., Eliaschewitz, F.G., Jódar, E., Leiter, L.A., et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med, 2016, 10.1056/NEJMoa1607141 (NEJMoa1607141).
14. [14] Steg, P.G., Roussel, R., Randomized trials to evaluate cardiovascular safety of antihyperglycemic medications. Circulation 134 (2016), 571–573, 10.1161/CIRCULATIONAHA.116.021914.